PMID- 32783291
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 2410-8650 (Electronic)
IS  - 1607-551X (Linking)
VI  - 36
IP  - 12
DP  - 2020 Dec
TI  - The deubiquitinase USP34 stabilizes SOX2 and induces cell survival and drug 
      resistance in laryngeal squamous cell carcinoma.
PG  - 983-989
LID - 10.1002/kjm2.12285 [doi]
AB  - Recent studies showed that the deubiquitinase ubiquitin-specific protease 34 
      (USP34) was involved in the tumorigenesis of several tumors, but its function and 
      mechanism are still unclear in laryngeal squamous cell carcinoma (LSCC). In this 
      study, we found that USP34 and SOX2 were elevated in LSCC tumor tissues, and we 
      also found that USP34 expression was positively correlated with SOX2 expression. 
      Our further studies showed that USP34 regulated the protein level of SOX2 in LSCC 
      cells, but not the mRNA level, which suggested that USP34 stabilized SOX2. 
      Moreover, USP34, as a deubiquitinase, could interact with SOX2, and reduce the 
      polyubiquitination of SOX2. In addition, knockdown of USP34 could significantly 
      inhibit LSCC cell growth, but overexpression of SOX2 could reverse this effect. 
      Finally, we also found that USP34 and SOX2 were upregulated in 
      cisplatin-resistant LSCC cells, but knockdown of USP34 could enhance the drug 
      sensitivity of cisplatin in the resistant cells. Collectively, targeting 
      USP34/SOX2 axis may be a promising strategy for the treatment of LSCC.
CI  - (c) 2020 The Authors. The Kaohsiung Journal of Medical Sciences published by John 
      Wiley & Sons Australia on behalf of Kaohsiung Medical University.
FAU - Dai, Wei-Li
AU  - Dai WL
AUID- ORCID: 0000-0002-0534-4385
AD  - Department of Otolaryngology, Division of Disease Control and Prevention, Office 
      of Hospital Infection Management, Beijing Hospital of Traditional Chinese 
      Medicine Affiliated to Capital Medical University, Beijing, P.R. China.
FAU - Yuan, Shu-Xian
AU  - Yuan SX
AD  - Department of Otolaryngology, Beijing Pinggu Hospital of Traditional Chinese 
      Medicine, Beijing, P.R. China.
FAU - Cao, Jing-Peng
AU  - Cao JP
AD  - Department of Otolaryngology, Lhasa People's Hospital, Lhasa, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 0 (SOX2 protein, human)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 120904-94-1 (Polyubiquitin)
RN  - EC 3.4.19.12 (USP34 protein, human)
RN  - EC 3.4.19.12 (Ubiquitin-Specific Proteases)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cisplatin/pharmacology
MH  - *Drug Resistance, Neoplasm/drug effects/genetics
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - HEK293 Cells
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Polyubiquitin/metabolism
MH  - Protein Binding/drug effects
MH  - Protein Stability/drug effects
MH  - SOXB1 Transcription Factors/genetics/*metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/genetics/*pathology
MH  - Ubiquitin-Specific Proteases/genetics/*metabolism
MH  - Ubiquitination/drug effects
OTO - NOTNLM
OT  - LSCC
OT  - SOX2
OT  - USP34
OT  - cell survival
OT  - drug resistance
EDAT- 2020/08/13 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/08/13 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/06/13 00:00 [revised]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2020/08/13 06:00 [entrez]
AID - 10.1002/kjm2.12285 [doi]
PST - ppublish
SO  - Kaohsiung J Med Sci. 2020 Dec;36(12):983-989. doi: 10.1002/kjm2.12285. Epub 2020 
      Aug 12.